Maze Therapeutics, Inc. - 8-K Filing
Maze Therapeutics reported Q1 2026 financial results with $362.9 million in cash and marketable securities as of March 31, driven by a $150 million registered offering and a $20 million milestone payment from Shionogi & Co., Ltd. for MZE001. The company reported license revenue of $20.0 million due to the achievement of this milestone under its agreement with Shionogi. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $MAZE